DNA minor groove guanine N2

This target refers to the N2 position of guanine residues located within the minor groove of DNA, specifically within sequence motifs such as CGG, AGC, AGG, and TGG (Pommier et al., 1996, Biochemistry). It is the molecular target for a class of synthetic and marine-derived alkaloids, most notably trabectedin and lurbinectedin (D'Incalci & Galmarini, 2010, Mol Cancer Ther). Unlike traditional alkylating agents that target the major groove, these drugs bind covalently to the minor groove, causing the DNA helix to bend toward the major groove (Takahashi et al., 2016, Cancer Sci). This structural alteration disrupts the binding of transcription factors to their cognate sequences, thereby inhibiting the expression of oncogenic drivers. Furthermore, the drug-DNA adduct interacts with the transcription-coupled nucleotide excision repair (TC-NER) machinery (Soares et al., 2007, BMC Cancer). Instead of being repaired, the lesion causes the TC-NER proteins to stall and induce DNA double-strand breaks, leading to cell cycle arrest and apoptosis. This target is clinically significant in the treatment of soft tissue sarcomas and small cell lung cancer, where these transcriptional and repair interferences are therapeutically exploited (Zelek et al., 2006, Annals of Oncology). The efficacy of targeting these residues is often dependent on the cell's DNA repair status, making it a unique focal point for precision oncology.

Other names

Guanine N2 positionDNA minor grooveTrabectedin-DNA binding siteLurbinectedin-DNA binding siteDNA minor groove guanine residues at CGG/AGC/AGG/TGG triplets

Covalent alkylation of the N2 position of guanine in the DNA minor groove, leading to DNA bending and interference with transcription-coupled nucleotide excision repair (TC-NER).